Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AX Other antivirals
J05AX24 Tecovirimat
D11557 Tecovirimat hydrate (JAN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D11557 Tecovirimat hydrate (JAN)
Drug groups [BR:br08330]
Metabolizing enzyme inhibitor
DG01641 CYP2C8 inhibitor
DG03049 Tecovirimat
D11557 Tecovirimat hydrate
DG01933 CYP2C19 inhibitor
DG03049 Tecovirimat
D11557 Tecovirimat hydrate
Metabolizing enzyme inducer
DG02891 CYP2B6 inducer
DG03049 Tecovirimat
D11557 Tecovirimat hydrate
DG02853 CYP3A/CYP3A4 inducer
DG01635 CYP3A4 inducer
DG03049 Tecovirimat
D11557 Tecovirimat hydrate
Antimicrobials [BR:br08307]
Antivirals
Entry, fusion or uncoating inhibitor
Herpesvirus glycoprotein
D11557 Tecovirimat hydrate (JAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11557
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11557
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11557
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11557
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11557
Drug groups [BR:br08330]
Metabolizing enzyme inhibitor
DG01641 CYP2C8 inhibitor
DG03049 Tecovirimat
DG01933 CYP2C19 inhibitor
DG03049 Tecovirimat
Metabolizing enzyme inducer
DG02891 CYP2B6 inducer
DG03049 Tecovirimat
DG02853 CYP3A/CYP3A4 inducer
DG01635 CYP3A4 inducer
DG03049 Tecovirimat